Drug Profile
AP PA01
Alternative Names: AB PA01; Ampliphage 001; AP-PA01; Bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections; BioPhage-PA; BioPhage-PRLatest Information Update: 06 Apr 2021
Price :
$50
*
At a glance
- Originator Biocontrol
- Developer AmpliPhi Biosciences Corporation; Armata Pharmaceuticals; Westmead Institute for Medical Research
- Class Antibacterials; Antiglaucomas; Bacteriophages; Quinoxalines; Vasoconstrictors
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pseudomonal infections